INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 8 04:35 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION AND GRANTED PRIORITY REVIEW DESIGNATION FOR SINTILIMAB COMBINATION WITH FRUQUINTINIB FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER
Apr 2 00:25 ET
INNOVENT BIO: PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Mar 20 09:41 ET
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Mar 6 09:40 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SECOND NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)
Mar 4 18:30 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF IBI311 MET THE PRIMARY ENDPOINT IN TREATING THYROID EYE DISEASE
Feb 19 18:30 ET
INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Feb 9 06:08 ET
INNOVENT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE
Feb 9 06:01 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE FIRST NEW DRUG APPLICATION FOR MAZDUTIDE FOR CHRONIC WEIGHT MANAGEMENT
Feb 7 03:30 ET
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Feb 6 05:11 ET
INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023
Feb 6 04:19 ET
INNOVENT BIO: RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER
Feb 5 03:30 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Jan 8 18:30 ET
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Jan 5 09:55 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (2023 VERSION) OF TYVYT''S SEVENTH INDICATION AND BYVASDA''S EIGHTH INDICATION
Dec 12, 2023 23:01 ET
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Dec 6, 2023 04:16 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO THE NEW DRUG APPLICATION FOR IBI-351 (KRAS G12C INHIBITOR)
Nov 23, 2023 19:15 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)
Nov 22, 2023 03:43 ET
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES OLVEREMBATINIB FOR THE TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT
Nov 17, 2023 09:13 ET
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Nov 6, 2023 05:34 ET
No Data
No Data